drugset / Trial / NCT07406399

Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia

NCT07406399

Phase 4 Completed 120 enrolled Beijing Tongren Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Peripheral contact lens in controlling myopia progression in high myopia children(PAM)is a prospective, single-center, randomized controlled trial with three parallel arms conducted at Beijing Tongren Hospital. Chinese children aged 6-12 years with high myopia (spherical equivalent ≤-6.0D) and annual progression ≥0.75D will be enrolled. Participants will be randomized 40:40:40 to: (1) combination therapy group receiving atropine 0.04% plus soft peripheral defocus contact lenses; (2) atropine monotherapy group receiving atropine 0.04% plus spectacles; or (3) control group receiving atropine 0.01% plus spectacles. The primary outcome is change in axial length and cycloplegic refraction at 24 months. Secondary outcomes include changes in pupil diameter, and safety parameters.

Timeline

Start
2023-06-30
Primary completion
2025-11-30
Completion
2026-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Atropine Other / unclassified 0.01 % Topical
Subject Atropine Other / unclassified 0.04 % Topical